866-997-4948(US-Canada Toll Free)

Histone Deacetylase 1 (HDAC1 or EC 3.5.1.98) - Pipeline Review, H2 2016

Published By :

Global Markets Direct

Published Date : Oct 2016

Category :

Pharmaceutical

No. of Pages : 110 Pages

Histone Deacetylase 1 (HDAC1 or EC 3.5.1.98) - Pipeline Review, H2 2016

Summary

Global Markets Directs, Histone Deacetylase 1 (HDAC1 or EC 3.5.1.98) - Pipeline Review, H2 2016, provides in depth analysis on Histone Deacetylase 1 (HDAC1 or EC 3.5.1.98) targeted pipeline therapeutics.

The report provides comprehensive information on the Histone Deacetylase 1 (HDAC1 or EC 3.5.1.98) , targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in Histone Deacetylase 1 (HDAC1 or EC 3.5.1.98) targeted therapeutics development and features dormant and discontinued projects.

Global Markets Directs report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Directs proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note:
*Certain sections in the report may be removed or altered based on the availability and relevance of data.
*Updated report will be delivered in 48 hours of order confirmation.

Scope

- The report provides a snapshot of the global therapeutic landscape for Histone Deacetylase 1 (HDAC1 or EC 3.5.1.98)
- The report reviews Histone Deacetylase 1 (HDAC1 or EC 3.5.1.98) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in Histone Deacetylase 1 (HDAC1 or EC 3.5.1.98) targeted therapeutics and enlists all their major and minor projects
- The report assesses Histone Deacetylase 1 (HDAC1 or EC 3.5.1.98) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news and deals related to Histone Deacetylase 1 (HDAC1 or EC 3.5.1.98) targeted therapeutics

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand the targeted therapy areas and indications for Histone Deacetylase 1 (HDAC1 or EC 3.5.1.98)
- Identify the use of drugs for target identification and drug repurposing
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and its most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Histone Deacetylase 1 (HDAC1 or EC 3.5.1.98) development landscape
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
Table of Contents
Table of Contents 2
List of Tables 5
List of Figures 6
Introduction 7
Global Markets Direct Report Coverage 7
Histone Deacetylase 1 (HDAC1 or EC 3.5.1.98) Overview 8
Therapeutics Development 9
Histone Deacetylase 1 (HDAC1 or EC 3.5.1.98) - Products under Development by Stage of Development 9
Histone Deacetylase 1 (HDAC1 or EC 3.5.1.98) - Products under Development by Therapy Area 10
Histone Deacetylase 1 (HDAC1 or EC 3.5.1.98) - Products under Development by Indication 11
Histone Deacetylase 1 (HDAC1 or EC 3.5.1.98) - Pipeline Products Glance 13
Late Stage Products 13
Early Stage Products 14
Histone Deacetylase 1 (HDAC1 or EC 3.5.1.98) - Products under Development by Companies 15
Histone Deacetylase 1 (HDAC1 or EC 3.5.1.98) - Products under Development by Universities/Institutes 21
Histone Deacetylase 1 (HDAC1 or EC 3.5.1.98) - Therapeutics Assessment 23
Assessment by Monotherapy/Combination Products 23
Assessment by Mechanism of Action 24
Assessment by Route of Administration 25
Assessment by Molecule Type 27
Histone Deacetylase 1 (HDAC1 or EC 3.5.1.98) - Companies Involved in Therapeutics Development 29
4SC AG 29
Acetylon Pharmaceuticals, Inc. 30
Chipscreen Biosciences Ltd 31
Curis, Inc. 32
GlaxoSmithKline Plc 33
HitGen LTD 34
IRBM Science Park SpA 35
Italfarmaco S.p.A. 36
MEI Pharma, Inc. 37
Merck & Co., Inc. 38
Mirati Therapeutics Inc. 39
Oncolys BioPharma Inc 40
Sigma-Tau S.p.A. 41
Syndax Pharmaceuticals Inc 42
TetraLogic Pharmaceuticals 43
Histone Deacetylase 1 (HDAC1 or EC 3.5.1.98) - Drug Profiles 44
4SC-202 - Drug Profile 44
Product Description 44
Mechanism Of Action 44
R&D Progress 44
ACY-738 - Drug Profile 47
Product Description 47
Mechanism Of Action 47
R&D Progress 47
ACY-957 - Drug Profile 48
Product Description 48
Mechanism Of Action 48
R&D Progress 48
crocetin - Drug Profile 50
Product Description 50
Mechanism Of Action 50
R&D Progress 50
CS-3158 - Drug Profile 51
Product Description 51
Mechanism Of Action 51
R&D Progress 51
CUDC-907 - Drug Profile 52
Product Description 52
Mechanism Of Action 52
R&D Progress 52
entinostat - Drug Profile 57
Product Description 57
Mechanism Of Action 57
R&D Progress 57
givinostat - Drug Profile 64
Product Description 64
Mechanism Of Action 64
R&D Progress 64
HG-3001 - Drug Profile 66
Product Description 66
Mechanism Of Action 66
R&D Progress 66
Largazole - Drug Profile 67
Product Description 67
Mechanism Of Action 67
R&D Progress 67
mocetinostat - Drug Profile 68
Product Description 68
Mechanism Of Action 68
R&D Progress 68
OBP-801 - Drug Profile 73
Product Description 73
Mechanism Of Action 73
R&D Progress 73
pracinostat - Drug Profile 74
Product Description 74
Mechanism Of Action 74
R&D Progress 74
remetinostat - Drug Profile 80
Product Description 80
Mechanism Of Action 80
R&D Progress 80
Small Molecule to Inhibit HDAC1, HDAC3 and HDAC6 for Lung Adenocarcinoma - Drug Profile 82
Product Description 82
Mechanism Of Action 82
R&D Progress 82
Small Molecule to Inhibit Histone Deacetylase 1 for Beta Thalassemia - Drug Profile 83
Product Description 83
Mechanism Of Action 83
R&D Progress 83
Small Molecule to Inhibit Histone Deacetylases for Oncology - Drug Profile 84
Product Description 84
Mechanism Of Action 84
R&D Progress 84
Small Molecules to Inhibit BRD4 and HDAC1 for Oncology - Drug Profile 85
Product Description 85
Mechanism Of Action 85
R&D Progress 85
Small Molecules to Inhibit HDAC1, HDAC2 and HDAC3 for Oncology - Drug Profile 86
Product Description 86
Mechanism Of Action 86
R&D Progress 86
ST-3595 - Drug Profile 87
Product Description 87
Mechanism Of Action 87
R&D Progress 87
tucidinostat - Drug Profile 88
Product Description 88
Mechanism Of Action 88
R&D Progress 88
vorinostat - Drug Profile 91
Product Description 91
Mechanism Of Action 91
R&D Progress 91
Histone Deacetylase 1 (HDAC1 or EC 3.5.1.98) - Dormant Projects 95
Histone Deacetylase 1 (HDAC1 or EC 3.5.1.98) - Featured News & Press Releases 99
Aug 01, 2016: MEI Pharmas Pracinostat Receives Breakthrough Therapy Designation from FDA for Treatment in Combination with Azacitidine of Patients with Newly Diagnosed Acute Myeloid Leukemia Unfit for Intensive Chemotherapy 99
Jun 08, 2016: Curis Announces Oral Presentation of Clinical Data Update from the Phase 1 Study of CUDC-907 at the 21st Congress of the European Hematology Association 99
Jun 05, 2016: Mirati Therapeutics Provides Update On Mocetinostat Program 100
Jun 02, 2016: Curis Announces Presentations Related to CUDC-907 at 2016 ASCO Annual Meeting 100
May 18, 2016: Entinostat Data to be Highlighted at the American Society of Clinical Oncology 2016 Annual Meeting 100
May 04, 2016: Acetylon Pharmaceuticals Publishes New Mechanism for the Treatment of Sickle Cell Disease/Beta-Thalassemia with Selective HDAC1/2 Inhibition in PLoS One 101
Apr 11, 2016: Syndax Announces Entinostat Data to be Presented at the American Association for Cancer Research (AACR) 2016 Annual Meeting 102
Apr 11, 2016: Curis Announces Presentation of Preclinical Data for CUDC-907 at AACR Annual Meeting 104
Apr 04, 2016: Curis Announces Publication of CUDC-907 Phase 1 Clinical Trial Data in Lancet Oncology 104
Mar 24, 2016: Mirati Therapeutics To Present Mocetinostat Preclinical Data At 2016 American Association For Cancer Research Annual Meeting 104
Mar 21, 2016: Epigenetic compound 4SC-202 strengthens endogenous immune response to cancer 105
Mar 03, 2016: HUYA Bioscience International Expands Senior Management Team 105
Dec 22, 2015: Huya Bioscience International Announces Orphan Drug Designation For HBI-8000 In Japan 106
Dec 07, 2015: MEI Pharma Announces Positive Results from Phase II Study of Pracinostat in Acute Myeloid Leukemia, Plans to Initiate Phase III Registration Study 106
Dec 07, 2015: Acetylon Presents Data on the Pharmacokinetics and HbE/HbG Hemoglobin Induction Following Once Daily Dosing of an Oral HDAC1,2 Inhibitor in Animal Models 107
Appendix 109
Methodology 109
Coverage 109
Secondary Research 109
Primary Research 109
Expert Panel Validation 109
Contact Us 109
Disclaimer 110

List of Tables
Number of Products under Development for, H2 2016 9
Number of Products under Development by Therapy Area, H2 2016 10
Number of Products under Development by Indication, H2 2016 11
Comparative Analysis by Late Stage Development, H2 2016 13
Comparative Analysis by Early Stage Products, H2 2016 14
Number of Products under Development by Companies, H2 2016 15
Products under Development by Companies, H2 2016 16
Products under Development by Companies, H2 2016 (Contd..1) 17
Products under Development by Companies, H2 2016 (Contd..2) 18
Products under Development by Companies, H2 2016 (Contd..3) 19
Products under Development by Companies, H2 2016 (Contd..4) 20
Number of Products under Investigation by Universities/Institutes, H2 2016 21
Products under Investigation by Universities/Institutes, H2 2016 22
Assessment by Monotherapy/Combination Products, H2 2016 23
Number of Products by Stage and Mechanism of Action, H2 2016 24
Number of Products by Stage and Route of Administration, H2 2016 26
Number of Products by Stage and Molecule Type, H2 2016 28
Pipeline by 4SC AG, H2 2016 29
Pipeline by Acetylon Pharmaceuticals, Inc., H2 2016 30
Pipeline by Chipscreen Biosciences Ltd, H2 2016 31
Pipeline by Curis, Inc., H2 2016 32
Pipeline by GlaxoSmithKline Plc, H2 2016 33
Pipeline by HitGen LTD, H2 2016 34
Pipeline by IRBM Science Park SpA, H2 2016 35
Pipeline by Italfarmaco S.p.A., H2 2016 36
Pipeline by MEI Pharma, Inc., H2 2016 37
Pipeline by Merck & Co., Inc., H2 2016 38
Pipeline by Mirati Therapeutics Inc., H2 2016 39
Pipeline by Oncolys BioPharma Inc, H2 2016 40
Pipeline by Sigma-Tau S.p.A., H2 2016 41
Pipeline by Syndax Pharmaceuticals Inc, H2 2016 42
Pipeline by TetraLogic Pharmaceuticals, H2 2016 43
Dormant Projects, H2 2016 95
Dormant Projects (Contd..1), H2 2016 96
Dormant Projects (Contd..2), H2 2016 97
Dormant Projects (Contd..3), H2 2016 98

List of Figures
Number of Products under Development for, H2 2016 9
Number of Products under Development by Therapy Area, H2 2016 10
Number of Products under Development by Top 10 Indication, H2 2016 11
Comparative Analysis by Late Stage Development, H2 2016 13
Comparative Analysis by Early Stage Products, H2 2016 14
Assessment by Monotherapy/Combination Products, H2 2016 23
Number of Products by Stage and Mechanism of Actions, H2 2016 24
Number of Products by Routes of Administration, H2 2016 25
Number of Products by Stage and Routes of Administration, H2 2016 25
Number of Products by Molecule Types, H2 2016 27
Number of Products by Stage and Molecule Type, H2 2016 27

Make an enquiry before buying this Report

Please fill the enquiry form below.

  • Full Name *
  • Your Email *
  • Job Title *
  • Company *
  • Phone No. * (Pls. Affix Country Code)
  • Message
  • Security Code *